Clinical Scorecard: Dry Eye: Conquering Coexisting Diseases
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease (DED) in Glaucoma Patients |
| Key Mechanisms | Topical glaucoma medications, particularly those with preservatives, exacerbate DED; DED affects visual field (VF) test reliability. |
| Target Population | Glaucoma patients with coexisting dry eye disease. |
| Care Setting | Ophthalmology clinics and specialized dry eye treatment centers. |
Key Highlights
- Glaucoma patients have a higher prevalence of DED.
- Topical medications, especially those with preservatives, can worsen DED symptoms.
- Alternative treatments include SLT, SRDD, MIGS, and non-preserved medications.
- VR headset-based perimetry shows promise in improving tear film stability.
- DED can impact the reliability of visual field tests.
Guideline-Based Recommendations
Diagnosis
- Assess DED symptom severity in glaucoma patients.
- Consider the impact of DED on VF test reliability.
Management
- Utilize SLT, SRDD, and MIGS as alternatives to traditional drop therapies.
- Prescribe non-preserved glaucoma medications when possible.
Monitoring & Follow-up
- Regularly evaluate tear film stability and DED symptoms in glaucoma patients.
Risks
- Increased variability in VF tests due to DED may complicate glaucoma diagnosis and monitoring.
Patient & Prescribing Data
Glaucoma patients experiencing dry eye symptoms.
Alternative treatments may reduce DED symptoms and improve adherence to glaucoma management.
Clinical Best Practices
- Stay updated on advancements in DED management for glaucoma patients.
- Incorporate VR technology for improved testing and patient comfort.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
